Takeda’s gene therapy pivot leaves JCR behind after proof-of-concept preclinical test

JCR Pharmaceuticals has achieved proof of concept for its gene therapy technology—just in time to lose partner Takeda as the pharma pivots away from adeno-associated viruses.